FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal

Ionis lands a transformational FDA label expansion for Tryngolza — the first approved treatment to reduce pancreatitis risk in severe hypertriglyceridemia.

Merck KGaA writes an eleven-point-three billion dollar check for Bio-Techne, the Supreme Court hands Bayer a Roundup win, and healthcare crushes the S&P by over a hundred and fifty basis points. Packed Thursday.

Welcome to The Pharma Closeout for Thursday, June 25th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it. ### [TOP STORY] — Ionis Tryngolza FDA Label Expansion

Starting with Ionis. The FDA today approved an expanded indication for Tryngolza — olezarsen — making it the first treatment indicated to reduce the risk of acute pancreatitis associated with severe hypertriglyceridemia. The drug previously carried a narrow label for familial chylomicronemia syndrome — small patient pool, niche commercial profile. Today's expansion blows that open. BioPharma Dive is calling this a commercial inflection point for Ionis. Endpoints is flagging it as a potential blockbuster triglycerides indication.

The label language is what matters most here. This is not a triglyceride-lowering indication — it's a pancreatitis risk reduction indication. The FDA credited a hard clinical endpoint, not a surrogate biomarker move. That distinction reshapes payer conversations entirely, and it raises the bar for any competitor trying to follow with a lipid-panel-only story.

And for Ionis specifically, this is the narrative inflection that investors have waited years for. The company built one of the deepest antisense platforms in biopharma, but the knock has always been the same — brilliant science, underwhelming revenue. That gap between platform innovation and commercial results has defined the Ionis story. Today's label is the best shot they've had at closing it.

Slow down on the blockbuster framing for a moment. If payers treat this as broadly accessible preventive therapy, that thesis holds. But if they gate coverage behind documented pancreatitis events or specialist-only prescribing, the addressable population compresses fast despite the expanded label. The real conversion here isn't FDA — it's formulary. And we won't have visibility on that for at least a quarter.

On a related note — Recordati licensed a separate Ionis drug today, per Endpoints. We've been tracking Recordati's deal activity since CVC took them private, and this fits the rare disease portfolio build-out pattern we've flagged before.

The bottom line on Ionis: platform credibility was never the question — revenue trajectory was. Today's label creates the opportunity. Whether they convert it comes down to commercial execution over the next two to three quarters. That's the window.

Shifting to the deal side, and the headliner is substantial. Merck KGaA — that's Darmstadt, not Kenilworth — is acquiring Bio-Techne for eleven-point-three billion dollars, seventy-three dollars per share, all cash. Their largest acquisition in over a decade. Let's bring in Marcus Webb on this one.

The market response was immediate. Diagnostics and research as a subsector jumped two-point-five-five percent on the day, clearly lifted by that deal premium. Bio-Techne stock surged on the announcement. Now, different Merck — Merck and Co., ticker MRK, rose four-point-oh-two percent today, but that appears to be broader sector momentum rather than deal spillover. Two Mercks, two different catalysts.

Eleven-point-three billion is a statement. The read-through for mid-cap life sciences tools companies with differentiated reagent or diagnostics capabilities is blunt — you're either a target or you're positioning to be one. That consolidation wave is accelerating, not fading.

Elsewhere on the deal and funding side — rapid fire. Ollin raised three hundred and thirty million for pivotal trials of a Vabysmo challenger in ophthalmology, licensed from a China-based developer. One of the year's largest venture rounds, coming right after head-to-head data showed certain advantages over Roche's treatment. Novartis tapped Antares — a Scorpion Therapeutics spinout — with a hundred and five million upfront for small molecule discovery. RQ Bio pulled in a hundred and fifteen million for a preventive flu antibody. Oblenio Bio closed sixty-two million led by Pfizer Ventures for autoimmune disease. And Remix is going public via reverse merger with Passage Bio, taking Passage's Nasdaq listing for its mRNA degrader platform. A gene therapy shell becoming an RNA degrader company — worth watching as a signal of where this cycle is heading.

The Ollin round is the one that should get attention. Three hundred and thirty million for a pivotal-stage program with head-to-head data already in hand — that's not speculative capital. That's a commercial thesis with conviction behind it. If the pivotal results confirm, Roche has a genuine competitive problem in ophthalmology.

The ophthalmology space is quietly getting very competitive. But on the regulatory side, the story with the longest tail today came from the Supreme Court.

The Roundup litigation. The SCOTUS ruling blunts state-level claims against Bayer's glyphosate herbicide — and the implications go well beyond the courtroom. Bayer has spent years and billions managing this legal exposure, and the overhang has constrained capital allocation across both their pharma and crop science divisions. This ruling could materially reduce the remaining liability that's weighed on valuation and strategic flexibility.

What made the Roundup exposure so damaging wasn't just the settlement costs — it was the unpredictability. You can't model future legal liabilities when litigation scope keeps expanding state by state. If this ruling narrows that exposure, Bayer gets something almost as valuable as money: the ability to plan. Whether that's pharma R&D reinvestment, crop science, or M&A, the strategic optionality matters as much as the legal relief.

The real question is whether Bayer's leadership acts on the opening. Legal relief without strategic redeployment is a missed opportunity — and this management team has been criticized for exactly that pattern. Watch for commentary in the coming weeks on what they intend to do with the breathing room.

Separately, Achieve Life Sciences received a Complete Response Letter from the FDA today. No details disclosed on the specific deficiency.

And the ADC class divergence keeps sharpening. Gilead's Trodelvy nabbed its broad front-line TNBC approval yesterday, and the stock dipped one-point-oh-five percent today — textbook sell-the-news. Pfizer dropped one-point-five-four percent, with BioPharma Dive now describing the forty-three billion dollar Seagen acquisition as souring further after that late-stage lung cancer failure. One company stacking label expansions, the other absorbing late-stage misses. At some point that stops being bad luck and starts being a portfolio construction problem. Pfizer's leadership will need to decide whether the Seagen pipeline needs fundamental reprioritization rather than waiting for the next readout to break their way.

Looking ahead — the marquee catalyst is the Lilly orforglipron PDUFA on June 30th, five days out. We've been tracking the label question since March — specifically whether the FDA imposes dosing guidance that limits orforglipron's convenience advantage over oral semaglutide. That decision reshapes the oral obesity competitive landscape, and we'll have the first read as soon as it lands.

We've also previously flagged Novartis's pelacarsen cardiovascular outcomes data as expected before the end of this half — that clock runs out in five days too. On the broader sector, healthcare outperformed the S&P by over a hundred and fifty basis points today. Drug manufacturers rose one-point-six percent on the session and are up nearly nineteen percent year-to-date. AbbVie climbed three-point-five-one percent, still riding momentum from the ten-point-nine billion dollar Apogee acquisition. Whether that rally extends into next week tells you how durable the buy-side conviction is in AbbVie's immunology and derm expansion — or whether the premium is already priced in.

That's your Pharma Closeout for Thursday. Ionis hits a commercial inflection point with Tryngolza, Merck KGaA makes an eleven billion dollar bet on Bio-Techne, the Supreme Court shifts the legal map for Bayer, and the Gilead-Pfizer ADC divergence widens by the day — with Lilly's orforglipron decision looming next week. If this briefing saves you time, follow us on Spotify and drop a rating — we'll be back tomorrow with more. I'm Alex Mercer.

And I'm Maya Patel. Enjoy your Thursday evening — see you tomorrow. ### Episode Metadata **Title:** Ionis Tryngolza FDA Label Expansion Hits Commercial Inflection; Merck KGaA's $11.3B Bio-Techne Buy; SCOTUS Blunts Bayer Roundup Claims | Jun 25, 2026 **Description:** FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTUS limits Bayer Roundup state-level claims; Gilead-Pfizer ADC divergence deepens. **Tags:** Ionis, Tryngolza, olezarsen, hypertriglyceridemia, pancreatitis, FDA approval, Merck KGaA, Bio-Techne, Bayer, Roundup, SCOTUS, Gilead, Trodelvy, Pfizer, Seagen, ADC, AbbVie, Apogee, Ollin, Vabysmo, Novartis, Antares, pelacarsen, RQ Bio, Oblenio Bio, Remix, Passage Bio, Eli Lilly, orforglipron, Recordati, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #